Efficacy and Safety of Bortezomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Sun CY et al. Biosci Rep. 2017 Jul 13. pii: BSR20170304. doi: 10.1042/BSR20170304. [Epub ahead of print].

Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma(TUBA study).
Nakasone H et al. Hematol Oncol. 2017 Jul 6. doi: 10.1002/hon.2452. [Epub ahead of print].

In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.
Oostvogels R et al. Bone Marrow Transplant. 2017 Jul 10. doi: 10.1038/bmt.2017.141. [Epub ahead of print].

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL et al. J Clin Oncol. 2017 Jul 25:JCO2017726679. doi: 10.1200/JCO.2017.72.6679. [Epub ahead of print].

Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.
Partanen A et al. Transfusion. 2017 Jul 5. doi: 10.1111/trf.14220. [Epub ahead of print].

HCT-CI Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro M et al. Biol Blood Marrow Transplant. 2017 Jun 29. pii: S1083-8791(17)30523-2. doi: 10.1016/j.bbmt.2017.06.014. [Epub ahead of print].

Stimulation of Adrenergic Activity by Desipramine Enhances Hematopoietic Stem and Progenitor Cell Mobilization along with G-CSF in Multiple Myeloma – A Pilot Study.
Shastri A et al. Am J Hematol. 2017 Jul 4. doi: 10.1002/ajh.24843. [Epub ahead of print].

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Baertsch MA et al. Hematol Oncol. 2017 Jul 7. doi: 10.1002/hon.2462. [Epub ahead of print].

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.
Paludo J et al. Blood. 2017 Jul 6. pii: blood-2017-05-782961. doi: 10.1182/blood-2017-05-782961. [Epub ahead of print].

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.

Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better.
Minagawa K et al. Acta Haematol. 2017 Jul 20;138(1):52-54. doi: 10.1159/000478691. [Epub ahead of print].
Nakaya A et al. Acta Haematol. 2017 Jul 21;138(1):55-60. doi: 10.1159/000477792. [Epub ahead of print].